There are 2789 resources available
Q&A and live discussion
Presenter: Rebecca Lee
Session: Proffered Paper session - SARS-CoV-2 and cancer
Resources:
Slides
Webcast
Invited Discussant 1560O_PR and 1561O
Presenter: Anne-Marie Dingemans
Session: Proffered Paper session - SARS-CoV-2 and cancer
Resources:
Slides
Webcast
Q&A and live discussion
Presenter: Dorothy Keefe
Session: Proffered Paper session - Supportive and palliative care
Resources:
Slides
Webcast
Invited Discussant 1558O and 1559O
Presenter: Rebecca Lee
Session: Proffered Paper session - SARS-CoV-2 and cancer
Resources:
Slides
Webcast
1561O - The future of the oncology workforce since COVID-19: Results of the ESMO Resilience Task Force survey series
Presenter: Kok Haw Jonathan Lim
Session: Proffered Paper session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
1559O - Efficacy and toxicity of BNT162b2 vaccine in cancer patients
Presenter: Ithai Waldhorn
Session: Proffered Paper session - SARS-CoV-2 and cancer
Resources:
Abstract
Slides
Webcast
1098O - Nivolumab plus platinum-doublet chemotherapy as first-line therapy in unresectable, locally advanced or metastatic G3 neuroendocrine Neoplasms (NENs) of the gastroenteropancreatic (GEP) tract or unknown (UK) origin: Preliminary results from the phase II NICE-NEC trial (GETNE T1913)
Presenter: Maria Carmen Riesco-Martinez
Session: Proffered Paper session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
LBA58 - Results of the randomized, placebo (PL)-controlled phase II study evaluating the efficacy and safety of regorafenib (REGO) in patients (pts) with relapsed advanced or metastatic chordoma, on behalf of the French Sarcoma Group (FSG) and Unicancer
Presenter: Florence Duffaud
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
LBA59 - LMS-04 study: A randomised, multicenter, phase III study comparing doxorubicin alone versus doxorubicin with trabectedin followed by trabectedin in non-progressive patients as first-line therapy, in patients with metastatic or unresectable leiomyosarcoma - A French Sarcoma Group study
Presenter: Patricia Pautier
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast
1520O - REGISTRI: Regorafenib in first-line of KIT/PDGFR wild type advanced GIST: Capatalize the A Spanish (GEIS), Italian (ISG) and French Sarcoma Group (FSG) phase II trial
Presenter: Javier Martin Broto
Session: Proffered Paper session - Sarcoma
Resources:
Abstract
Slides
Webcast